Cat. No. : |
Eng-982M |
Description : |
Endoglin, also known as CD105, is a Type I integral membrane glycoprotein with a large, disulfide-linked, extracellular region and a short, constitutively phosphorylated, cytoplasmic tail. Endoglin is highly expressed on vascular endothelial cells, chondrocytes, and syncytiotrophoblasts of term placenta. It is also found on activated monocytes, bone marrow pro-erythroblasts, and leukemic cells of lymphoid and myeloid lineages. Human and mouse endoglin share approximately 70% and 97 % amino acid sequence identity in their extracellular and intracellular domains, respectively. In common with betaglycan (also named TßRIII), a proteoglycan that shares regions of sequence similarity, endoglin is an accessory receptor for the TGF- superfamily ligands. Endoglin does not bind ligands by itself, but does so by associating with a ligand-binding serine/threonine kinase receptor. Endoglin binds TGF-1 and TGF-3 but not TGF-2 efficiently by associating with TGF- type II receptor (TßRII). It interacts with activin-A and BMP-7 using either the activin type II or type IIB receptors. In the case of BMP-2 which binds directly to the type I but not the type II BMP receptor, endoglin binds via either BMPR-IA (ALK-3) or BMPR-1B (ALK-6). |
Source : |
Insect cells. |
Purity : |
> 95% (SDS-PAGE and visualized by Silverstain). |
Endotoxin level : |
< 0.1 ng per μg of sCD105. |
Stabilizer : |
None. |
Formulation : |
Lyophilized. |
Biologically Activity : |
Measured by its ability to bind with TGF- RII/Fc in a functional ELISA. Optimal dilutions should be determined by each laboratory for each application. |
Reconstitution : |
The carrier-free protein should be used immediately upon reconstitution to avoid losses in activity due to non-specific binding to the inside surface of the vial. For long term storage as a dilute solution, a carrier protein (e.g. 0.1% HSA or BSA) should be added to the vial. |
Stability : |
Upon reconstitution, this cytokine, in the presence of a carrier protein, can be stored under sterile conditions at -20°Cto -70°Cfor three months without detectable loss of activity. Avoid repeated freeze-thaw cycles. |